Once Daily Treatment for COPD

Trelegy Consumer Information

Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional’s advice.

References: 1. Trelegy Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz. [Accessed Jun 2026]. 2. Trelegy Ellipta Consumer Medicine Information, GSK New Zealand, available at www.medsafe.govt.nz. [Accessed Jun 2026]. 3. WHO: 2023; 1-5; Chronic obstructive pulmonary disease COPD. Available at www.who.int/ [Accessed Jun 2026]. 4. GOLD 2026  Report. Global Initiative for Chronic Obstructive Lung Disease. Available at www.goldcopd.org. [Accessed Jun 2026]. 5. COPD Assessment Test (CAT). Available at www.catestonline.org/ [Accessed Jun 2026]. 6. PHARMAC Pharmaceutical Schedule Accessed June 2026. Available at www.pharmac.govt.nz/pharmaceutical-schedule. [Accessed Jun 2026]. 7. Lipson DA et al, Adv Ther 2020;37;4894-4909. 8. Lipson DA, et al. Am J Respir Crit Care Med. 2017;196:438-446. 9. Lipson DA, et al. N Engl J Med. 2018;378:1671-1680. 10. Svedsater H. BMC Pulm Med;2013;13;1-14. 11. van der Palen J;npj Primary Care Respiratory Medicine;2016;26:16079;1-8.

Trelegy Ellipta (fluticasone furoate/umeclidinium [as bromide]/vilanterol [as trifenatate] inhaler 100/62.5/25mcg and 200/62.5/25mcg per dose powder for inhalation) is a Prescription Medicine. Trelegy Ellipta is used for the regular treatment of adults with asthma or chronic obstructive pulmonary disease (COPD). Trelegy Ellipta 100/62.5/25mcg is fully funded for patients with COPD only; Special Authority criteria apply. Use strictly as directed. Trelegy Ellipta has risks and benefits. Trelegy Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack, you must use a quick-acting (reliever) inhaler. Always carry your reliever inhaler. Do not discontinue Trelegy Ellipta unless advised by your doctor. Tell your doctor: if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop (this includes all of the medicines that you are using for your asthma or COPD); if you have liver disease, heart problems, high blood pressure, pulmonary tuberculosis (TB), infection of the lungs (pneumonia) or weak bones (osteoporosis); if you have had any type of viral, bacterial or fungal infection, or a problem with your immune system; if you have an enlarged prostate, difficulty passing urine, or a blockage in your bladder; if you have eye problems such as glaucoma or cataracts; if you are pregnant, think you may be pregnant, are planning to have a baby, or are breast-feeding; if you have severe milk-protein allergy; or if you are allergic to fluticasone furoate, umeclidinium, vilanterol or any of the other ingredients in Trelegy Ellipta. Side effects: Oral thrush, headache, cough, hoarseness, painful and frequent urination, joint pain, back pain, constipation; itchy, runny or blocked nose; pain in the back of the mouth and throat; inflammation of the sinuses; inflammation of the lungs (bronchitis); flu (influenza); infection of the nose, sinuses or throat; infection of the upper airways; infection of the lungs (pneumonia); irregular or faster heart beat; dry mouth; taste disturbance; weakening of the bones, leading to fractures. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. For more information see Trelegy Ellipta Consumer Medicine Information www.medsafe.govt.nz . Ask your doctor if Trelegy Ellipta is right for you. Normal doctor’s charges apply.

Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. Date of Approval: 06 2026 Date of Expiry: 06 2028 TAPS NP24966 PM-NZ-FVU-WCNT-260001